S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
LON:UDG

UDG Healthcare Competitors

GBX 771.50
-0.50 (-0.06 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
759
Now: GBX 771.50
783
50-Day Range
755
MA: GBX 795.91
839
52-Week Range
423.40
Now: GBX 771.50
849.50
Volume882,179 shs
Average Volume459,990 shs
Market Capitalization£1.94 billion
P/E Ratio20.96
Dividend Yield1.64%
BetaN/A

Competitors

UDG Healthcare (LON:UDG) Vs. HIK, ABC, CTEC, DPH, GNS, and BTG

Should you be buying UDG stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to UDG Healthcare, including Hikma Pharmaceuticals (HIK), Abcam plc (ABC.L) (ABC), Convatec Group (CTEC), Dechra Pharmaceuticals PLC (DPH.L) (DPH), Genus plc (GNS.L) (GNS), and BTG (BTG).

Hikma Pharmaceuticals (LON:HIK) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Dividends

Hikma Pharmaceuticals pays an annual dividend of GBX 0.47 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Hikma Pharmaceuticals pays out 0.2% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Hikma Pharmaceuticals and UDG Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hikma PharmaceuticalsN/AN/AN/A
UDG HealthcareN/AN/AN/A

Valuation and Earnings

This table compares Hikma Pharmaceuticals and UDG Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£2.29 billion2.25N/AGBX 211.1010.59
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96

Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than UDG Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Hikma Pharmaceuticals and UDG Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hikma Pharmaceuticals02602.75
UDG Healthcare01502.83

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,478.57, suggesting a potential upside of 10.85%. UDG Healthcare has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe UDG Healthcare is more favorable than Hikma Pharmaceuticals.

Summary

Hikma Pharmaceuticals beats UDG Healthcare on 5 of the 9 factors compared between the two stocks.

Abcam plc (ABC.L) (LON:ABC) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Abcam plc (ABC.L) and UDG Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abcam plc (ABC.L)£260 million14.79N/AGBX 6282.67
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96

UDG Healthcare is trading at a lower price-to-earnings ratio than Abcam plc (ABC.L), indicating that it is currently the more affordable of the two stocks.

Dividends

Abcam plc (ABC.L) pays an annual dividend of GBX 0.12 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Abcam plc (ABC.L) pays out 2.0% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UDG Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Abcam plc (ABC.L) and UDG Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam plc (ABC.L)04202.33
UDG Healthcare01502.83

Abcam plc (ABC.L) currently has a consensus price target of GBX 1,420, suggesting a potential downside of 16.27%. UDG Healthcare has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe UDG Healthcare is more favorable than Abcam plc (ABC.L).

Profitability

This table compares Abcam plc (ABC.L) and UDG Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abcam plc (ABC.L)N/AN/AN/A
UDG HealthcareN/AN/AN/A

Summary

UDG Healthcare beats Abcam plc (ABC.L) on 7 of the 9 factors compared between the two stocks.

UDG Healthcare (LON:UDG) and Convatec Group (LON:CTEC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares UDG Healthcare and Convatec Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96
Convatec Group£1.85 billion2.05N/AGBX 1.20157.00

UDG Healthcare is trading at a lower price-to-earnings ratio than Convatec Group, indicating that it is currently the more affordable of the two stocks.

Dividends

UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Convatec Group pays an annual dividend of GBX 0.06 per share and has a dividend yield of 0.0%. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Convatec Group pays out 4.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a summary of recent ratings and recommmendations for UDG Healthcare and Convatec Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UDG Healthcare01502.83
Convatec Group36201.91

UDG Healthcare currently has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Convatec Group has a consensus price target of GBX 206, suggesting a potential upside of 9.34%. Given UDG Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe UDG Healthcare is more favorable than Convatec Group.

Profitability

This table compares UDG Healthcare and Convatec Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UDG HealthcareN/AN/AN/A
Convatec GroupN/AN/AN/A

Summary

UDG Healthcare beats Convatec Group on 5 of the 9 factors compared between the two stocks.

UDG Healthcare (LON:UDG) and Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96
Dechra Pharmaceuticals PLC (DPH.L)£515.10 million7.20N/AGBX 32.80104.57

UDG Healthcare is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals PLC (DPH.L), indicating that it is currently the more affordable of the two stocks.

Dividends

UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Dechra Pharmaceuticals PLC (DPH.L) pays an annual dividend of GBX 0.32 per share and has a dividend yield of 0.0%. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Dechra Pharmaceuticals PLC (DPH.L) pays out 1.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UDG Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a summary of recent ratings and recommmendations for UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UDG Healthcare01502.83
Dechra Pharmaceuticals PLC (DPH.L)02202.50

UDG Healthcare currently has a consensus price target of GBX 897.50, suggesting a potential upside of 16.33%. Dechra Pharmaceuticals PLC (DPH.L) has a consensus price target of GBX 3,077.50, suggesting a potential downside of 10.28%. Given UDG Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe UDG Healthcare is more favorable than Dechra Pharmaceuticals PLC (DPH.L).

Profitability

This table compares UDG Healthcare and Dechra Pharmaceuticals PLC (DPH.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UDG HealthcareN/AN/AN/A
Dechra Pharmaceuticals PLC (DPH.L)N/AN/AN/A

Summary

UDG Healthcare beats Dechra Pharmaceuticals PLC (DPH.L) on 7 of the 9 factors compared between the two stocks.

Genus plc (GNS.L) (LON:GNS) and UDG Healthcare (LON:UDG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Genus plc (GNS.L) and UDG Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genus plc (GNS.L)01202.67
UDG Healthcare01502.83

Genus plc (GNS.L) presently has a consensus target price of GBX 4,155, suggesting a potential downside of 17.48%. UDG Healthcare has a consensus target price of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe UDG Healthcare is more favorable than Genus plc (GNS.L).

Earnings and Valuation

This table compares Genus plc (GNS.L) and UDG Healthcare's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genus plc (GNS.L)£551.40 million5.96N/AGBX 61.9081.34
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96

UDG Healthcare is trading at a lower price-to-earnings ratio than Genus plc (GNS.L), indicating that it is currently the more affordable of the two stocks.

Dividends

Genus plc (GNS.L) pays an annual dividend of GBX 0.28 per share and has a dividend yield of 0.0%. UDG Healthcare pays an annual dividend of GBX 0.17 per share and has a dividend yield of 0.0%. Genus plc (GNS.L) pays out 0.5% of its earnings in the form of a dividend. UDG Healthcare pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Genus plc (GNS.L) and UDG Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genus plc (GNS.L)N/AN/AN/A
UDG HealthcareN/AN/AN/A

Summary

UDG Healthcare beats Genus plc (GNS.L) on 5 of the 9 factors compared between the two stocks.

BTG (LON:BTG) and UDG Healthcare (LON:UDG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BTG and UDG Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BTG0000N/A
UDG Healthcare01502.83

UDG Healthcare has a consensus target price of GBX 897.50, suggesting a potential upside of 16.33%. Given UDG Healthcare's higher probable upside, analysts plainly believe UDG Healthcare is more favorable than BTG.

Valuation and Earnings

This table compares BTG and UDG Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£914.10 million3.57N/AGBX 28.5029.47
UDG Healthcare£1.28 billion1.52N/AGBX 36.8020.96

UDG Healthcare is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BTG and UDG Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BTGN/AN/AN/A
UDG HealthcareN/AN/AN/A

Summary

UDG Healthcare beats BTG on 4 of the 6 factors compared between the two stocks.


UDG Healthcare Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hikma Pharmaceuticals logo
HIK
Hikma Pharmaceuticals
1.6$2,236.00-4.6%£5.15 billion£2.29 billion10.59Dividend Increase
High Trading Volume
News Coverage
Gap Down
Abcam plc (ABC.L) logo
ABC
Abcam plc (ABC.L)
0.7$1,696.00-2.7%£3.84 billion£260 million282.67News Coverage
Gap Up
Convatec Group logo
CTEC
Convatec Group
1.0$188.40-1.1%£3.78 billion£1.85 billion157.00Upcoming Earnings
News Coverage
Dechra Pharmaceuticals PLC (DPH.L) logo
DPH
Dechra Pharmaceuticals PLC (DPH.L)
0.9$3,430.00-0.6%£3.71 billion£515.10 million104.57Dividend Cut
Genus plc (GNS.L) logo
GNS
Genus plc (GNS.L)
1.0$5,035.00-1.7%£3.29 billion£551.40 million81.34Dividend Cut
Insider Buying
News Coverage
Gap Up
BTG logo
BTG
BTG
0.8$840.00-0.1%£3.26 billion£914.10 million29.47
Mediclinic International plc (MDC.L) logo
MDC
Mediclinic International plc (MDC.L)
0.9$285.40-2.5%£2.10 billion£2.98 billion-5.08
PureTech Health logo
PRTC
PureTech Health
1.5$413.50-1.2%£1.18 billion£12.26 million2.61News Coverage
Gap Down
Clinigen Group plc (CLIN.L) logo
CLIN
Clinigen Group plc (CLIN.L)
1.6$713.50-0.6%£949.16 million£504.30 million69.95Dividend Cut
Indivior PLC (INDV.L) logo
INDV
Indivior PLC (INDV.L)
1.4$128.50-0.4%£943.26 million£647 million-6.36
Oxford Biomedica plc (OXB.L) logo
OXB
Oxford Biomedica plc (OXB.L)
0.8$1,012.00-0.4%£833.62 million£65.94 million-61.71News Coverage
Gap Down
MaxCyte logo
MXCT
MaxCyte
0.5$980.00-3.1%£758.74 million£24.14 million-61.64
Vectura Group plc (VEC.L) logo
VEC
Vectura Group plc (VEC.L)
1.2$112.00-1.1%£667.47 million£176.30 million-93.33News Coverage
RENX
Renalytix AI plc (RENX.L)
0.6$855.00-0.6%£617.66 million£105,000.00-35.33Upcoming Earnings
Ergomed logo
ERGO
Ergomed
0.6$1,250.00-4.0%£609 million£73.46 million100.00News Coverage
Gap Up
UPR
Uniphar
0.2$214.00-1.6%£600.63 million£1.74 billion2,183.67News Coverage
Spire Healthcare Group logo
SPI
Spire Healthcare Group
1.1$146.60-2.3%£587.99 million£891.10 million-2.52Upcoming Earnings
Gap Down
CareTech logo
CTH
CareTech
1.6$510.00-0.8%£577.74 million£429.97 million23.18News Coverage
NCYT
Novacyt S.A. (NCYT.L)
0.4$701.04-5.8%£524.05 millionN/A-26.76
Advanced Medical Solutions Group logo
AMS
Advanced Medical Solutions Group
0.6$235.00-1.5%£506.36 million£92.94 million37.30
Consort Medical plc (CSRT.L) logo
CSRT
Consort Medical plc (CSRT.L)
0.9N/AN/A£504.60 million£298.60 million127.85
Avacta Group Plc (AVCT.L) logo
AVCT
Avacta Group Plc (AVCT.L)
0.5$195.00-1.0%£492.67 million£4.64 million-25.00Gap Up
Silence Therapeutics plc (SLN.L) logo
SLN
Silence Therapeutics plc (SLN.L)
0.7$590.00-0.3%£491.52 million£1.39 million-21.00Gap Down
Alliance Pharma logo
APH
Alliance Pharma
0.6$85.70-0.4%£456.94 million£131.34 million40.81
Benchmark logo
BMK
Benchmark
0.9$57.50-0.0%£388.11 million£109.90 million-13.37
Beximco Pharmaceuticals logo
BXP
Beximco Pharmaceuticals
0.5$86.00-0.0%£383.66 millionN/A0.00
Amryt Pharma logo
AMYT
Amryt Pharma
0.5$213.00-0.5%£380.85 million£180.38 million-3.72Upcoming Earnings
Gap Up
CREO
Creo Medical
0.5$218.15-2.7%£353.68 million£8,154.00-17.59
Synairgen logo
SNG
Synairgen
0.4$174.00-8.0%£347.85 million£79,000.00-34.12News Coverage
Gap Up
SPEC
Inspecs Group plc (SPEC.L)
1.3$323.20-0.6%£327.61 million£47.58 million-18.57
EKF Diagnostics Holdings plc (EKF.L) logo
EKF
EKF Diagnostics Holdings plc (EKF.L)
0.8$67.00-4.9%£304.85 million£49.81 million47.86News Coverage
Gap Down
ARIX
Arix Bioscience
1.2$189.00-1.1%£276.64 million£23.47 million13.50News Coverage
Tristel plc (TSTL.L) logo
TSTL
Tristel plc (TSTL.L)
0.6$590.00-1.5%£275.31 million£33.80 million52.68Dividend Cut
ECO Animal Health Group logo
EAH
ECO Animal Health Group
1.1$327.50-0.0%£221.22 million£86.32 million65.50Gap Down
Bioventix PLC (BVXP.L) logo
BVXP
Bioventix PLC (BVXP.L)
0.9$4,210.00-0.2%£219.30 million£10.31 million30.53
Tiziana Life Sciences PLC (TILS.L) logo
TILS
Tiziana Life Sciences PLC (TILS.L)
0.7$105.00-1.0%£204.34 millionN/A-19.09
ORPH
Open Orphan
0.0$28.75-0.2%£192.07 million£10.57 million-8.98
DDDD
4D pharma
0.6$135.09-8.1%£191.99 million£486,000.00-4.28High Trading Volume
Gap Up
Scancell Holdings plc (SCLP.L) logo
SCLP
Scancell Holdings plc (SCLP.L)
0.6$23.00-6.5%£187.50 millionN/A-16.43Gap Down
Redx Pharma Plc (REDX.L) logo
REDX
Redx Pharma Plc (REDX.L)
0.9$66.00-2.3%£178.03 million£5.69 million-12.22
ANGLE logo
AGL
ANGLE
0.4$81.80-3.3%£176.24 million£722,500.00-15.73Gap Down
Faron Pharmaceuticals Oy (FARN.L) logo
FARN
Faron Pharmaceuticals Oy (FARN.L)
0.6$327.50-0.8%£153.59 millionN/A-2.99News Coverage
Omega Diagnostics Group PLC (ODX.L) logo
ODX
Omega Diagnostics Group PLC (ODX.L)
0.3$83.00-1.2%£149.41 million£8.52 million-18.86
MGP
Medica Group
1.1$134.00-5.8%£149.12 million£41.55 million30.45Gap Up
Advanced Oncotherapy logo
AVO
Advanced Oncotherapy
0.4$40.50-1.2%£139.84 millionN/A-4.13
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50-1.9%£138.87 millionN/A-0.21Gap Up
SBI
Sourcebio International
0.0$186.00-0.5%£138.72 millionN/A0.00
ANCR
Animalcare Group plc (ANCR.L)
0.9$227.00-3.1%£136.33 million£69.52 million189.17Gap Down
ONC
Oncimmune Holdings plc (ONC.L)
0.4$212.00-0.0%£134.96 million£2.03 million-23.30News Coverage
VSN
Verseon
0.5$74.00-2.0%£127.41 millionN/A-5.17Gap Down
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.